还款模式
基于1个网页-相关网页
·2,447,543篇论文数据，部分数据来源于NoteExpress
Although we have sales in our model for Zaltrap, our model assigns no value to this asset as REGN will have to start repaying 50% of Zaltrap development expenses in all cancers as soon as this business becomes profitable.
FORBES: Why Regeneron May Not Profit Much From Today's FDA Approval
应用推荐
模块上移
模块下移
不移动